<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00740142</url>
  </required_header>
  <id_info>
    <org_study_id>Si 341/2008</org_study_id>
    <nct_id>NCT00740142</nct_id>
  </id_info>
  <brief_title>Efficacy of Combined Oral L-ornithine-L-aspartate and Lactulose in Patients With Hepatic Encephalopathy</brief_title>
  <official_title>Efficacy of Combined Oral L-ornithine-L-aspartate and Oral Lactulose in Patients With Hepatic Encephalopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: Is the combination of oral L-ornithine-L-aspartate and lactulose more efficacious&#xD;
      than oral lactulose alone in treatment of hepatic encephalopathy? Study design; Randomized,&#xD;
      double-blinded, placebo controlled trial&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data collection&#xD;
&#xD;
        1. Baseline characteristics&#xD;
&#xD;
             -  demographic data; age, gender, BW, height&#xD;
&#xD;
             -  cirrhosis; cause, duration, Child-Pugh score,complications of cirrhosis such as EV,&#xD;
                ascites, hepatic encephalopathy, SBP etc.&#xD;
&#xD;
             -  comorbidity such as DM, CVA&#xD;
&#xD;
        2. After randomization&#xD;
&#xD;
             -  assessment of mental status (West-Haven criteria), Portal-systemic encephalopathy&#xD;
                index (PSEI), number connection test, serum ammonia, asterixis at Day 1,3,7 and EEG&#xD;
                at day 1,7&#xD;
&#xD;
             -  blood chemistry such as CBC, BUN, Creatinine, electrolyte, LFT, coagulogram, BS at&#xD;
                Day 1,3,7&#xD;
&#xD;
             -  record adverse effect of drug such as nausea, vomiting, bloating.&#xD;
&#xD;
             -  record diet, frequency of bowel movement and stool pH&#xD;
&#xD;
             -  compliance&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess improvement of mental status of the patients</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess improvement of number connection test, serum ammonia, EEG, asterixis and PSE index of the patients</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Hepatic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Interventional arm: oral L-ornithine-L-aspartate and oral lactulose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral lactulose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-ornithine-L-aspartate and lactulose</intervention_name>
    <description>L-ornithine-L-aspartate 1 sachet(3 grams)3 times a day for 7 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo and lactulose</intervention_name>
    <description>placebo 3 times a day for 7 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cirrhosis&#xD;
&#xD;
          -  Age 18-80&#xD;
&#xD;
          -  Hepatic encephalopathy grade II-III&#xD;
&#xD;
          -  Serum ammonia &gt; 60 mcg/mL&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recent GI hemorrhage&#xD;
&#xD;
          -  Severe sepsis&#xD;
&#xD;
          -  Degenerative CNS disease or major psychiatric illness&#xD;
&#xD;
          -  Serum creatinine &gt; 1.5 mg/dl&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Poorly controlled DM&#xD;
&#xD;
          -  Insertion of TIPS&#xD;
&#xD;
          -  Received CNS depressants or hypnotics&#xD;
&#xD;
          -  Treatment with metronidazole, kanamycin or branched-chain amino acid&#xD;
&#xD;
          -  Hypersensitivity to L-ornithine-L-aspartate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Siwaporn Chainuvati, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Siriraj Hospital, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 21, 2008</study_first_submitted>
  <study_first_submitted_qc>August 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2008</study_first_posted>
  <last_update_submitted>September 2, 2020</last_update_submitted>
  <last_update_submitted_qc>September 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>L ornithine L aspartate</keyword>
  <keyword>Lactulose</keyword>
  <keyword>Hepatic encephalopathy</keyword>
  <keyword>LOLA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lactulose</mesh_term>
    <mesh_term>N-Methylaspartate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

